246
References
1. Spencer JPE et al (2003) Intracellular metabolism and bioactivity of quercetin and its vivo
metabolites. Biochem J 372(1):173–181
2. Smith AJ et al (2011) Cocrystals of quercetin
with improved solubility and oral bioavailability. Mol Pharm 8(5):1867–1876
3. Day AJ et al (2001) Human metabolism of
dietary flavonoids: identification of plasma
metabolites of quercetin. Free Radic Res
35(6):941–952
4. Ferry DR et al (1996) Phase I clinical trial of
the flavonoid quercetin: pharmacokinetics and
evidence for in vivo tyrosine kinase inhibition.
Clin Cancer Res 2(4):659–668
5. Figueiras A et al (2007) Solid-state characterization and dissolution profiles of the inclusion complexes of omeprazole with native and
chemically modified beta-cyclodextrin. Eur J
Pharm Biopharm 67(2):531–539
6. Mendes C et al (2015) Quantitative analysis of norfloxacin in β-cyclodextrin inclusion
complexes—development and validation of a
stability-indicating HPLC method. Anal Sci
31(10):1083–1089
7. Kellici TF et al (2016) Mapping the interactions and bioactivity of quercetin-(2hydroxypropyl)-β-cyclodextrin complex. Int J
Pharm 511(1):303–311
8. Malanga M et al (2016) “Back to the Future”: a
new look at hydroxypropyl beta- cyclodextrins.
J Pharm Sci 105(9):2921–2931
9. Pitha J et al (1992) Preparation of drug:
hydroxypropylcyclodextrin complexes by a
method using ethanol or aqueous ammonium hydroxide as co-solubilizers. Int J Pharm
80(1):253–258
10. Trinadha Rao C et al (1992) Distribution of
substituents in O-(2-hydroxypropyl) derivatives of cyclomalto-oligosaccharides (cyclodextrins): influence of increasing substitution, of
the base used in the preparation, and of macrocyclic size. Carbohydr Res 223:99–107
11. Tan SK et al (2018) Serum long noncoding
RNA HOTAIR as a novel diagnostic and prognostic biomarker in glioblastoma multiforme.
Mol Cancer 17(1):74
12. Stupp R et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996
13. Roos WP et al (2007) Apoptosis in malignant
glioma cells triggered by the temozolomideinduced DNA lesion O6-methylguanine.
Oncogene 26(2):186–197
14. Zhou Q et al (2007) Preclinical pharmacokinetic and pharmacodynamic evaluation of
metronomic and conventional temozolomide dosing regimens. J Pharmacol Exp Ther
321(1):265–275
15. Happold C et al (2012) Distinct molecular
mechanisms of acquired resistance to temozolomide in glioblastoma cells. J Neurochem
122(2):444–455
16. Renziehausen A et al (2019) Encapsulation
of temozolomide in a calixarene nanocapsule
improves its stability and enhances its therapeutic efficacy against glioblastoma. Mol Cancer
Ther 18(9):1497–1505
17. Webber MJ, Langer R (2017) Drug delivery by supramolecular design. Chem Soc Rev
46(21):6600–6620
18. Cohen Y, Avram L, Frish L (2005) Diffusion
NMR spectroscopy in supramolecular and combinatorial chemistry: an old parameter—new
insights. Angew Chem Int Ed 44(4):520–554
Christos M. Chatzigiannis et al.
References
1. Spencer JPE et al (2003) Intracellular metabolism and bioactivity of quercetin and its vivo
metabolites. Biochem J 372(1):173–181
2. Smith AJ et al (2011) Cocrystals of quercetin
with improved solubility and oral bioavailability. Mol Pharm 8(5):1867–1876
3. Day AJ et al (2001) Human metabolism of
dietary flavonoids: identification of plasma
metabolites of quercetin. Free Radic Res
35(6):941–952
4. Ferry DR et al (1996) Phase I clinical trial of
the flavonoid quercetin: pharmacokinetics and
evidence for in vivo tyrosine kinase inhibition.
Clin Cancer Res 2(4):659–668
5. Figueiras A et al (2007) Solid-state characterization and dissolution profiles of the inclusion complexes of omeprazole with native and
chemically modified beta-cyclodextrin. Eur J
Pharm Biopharm 67(2):531–539
6. Mendes C et al (2015) Quantitative analysis of norfloxacin in β-cyclodextrin inclusion
complexes—development and validation of a
stability-indicating HPLC method. Anal Sci
31(10):1083–1089
7. Kellici TF et al (2016) Mapping the interactions and bioactivity of quercetin-(2hydroxypropyl)-β-cyclodextrin complex. Int J
Pharm 511(1):303–311
8. Malanga M et al (2016) “Back to the Future”: a
new look at hydroxypropyl beta- cyclodextrins.
J Pharm Sci 105(9):2921–2931
9. Pitha J et al (1992) Preparation of drug:
hydroxypropylcyclodextrin complexes by a
method using ethanol or aqueous ammonium hydroxide as co-solubilizers. Int J Pharm
80(1):253–258
10. Trinadha Rao C et al (1992) Distribution of
substituents in O-(2-hydroxypropyl) derivatives of cyclomalto-oligosaccharides (cyclodextrins): influence of increasing substitution, of
the base used in the preparation, and of macrocyclic size. Carbohydr Res 223:99–107
11. Tan SK et al (2018) Serum long noncoding
RNA HOTAIR as a novel diagnostic and prognostic biomarker in glioblastoma multiforme.
Mol Cancer 17(1):74
12. Stupp R et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996
13. Roos WP et al (2007) Apoptosis in malignant
glioma cells triggered by the temozolomideinduced DNA lesion O6-methylguanine.
Oncogene 26(2):186–197
14. Zhou Q et al (2007) Preclinical pharmacokinetic and pharmacodynamic evaluation of
metronomic and conventional temozolomide dosing regimens. J Pharmacol Exp Ther
321(1):265–275
15. Happold C et al (2012) Distinct molecular
mechanisms of acquired resistance to temozolomide in glioblastoma cells. J Neurochem
122(2):444–455
16. Renziehausen A et al (2019) Encapsulation
of temozolomide in a calixarene nanocapsule
improves its stability and enhances its therapeutic efficacy against glioblastoma. Mol Cancer
Ther 18(9):1497–1505
17. Webber MJ, Langer R (2017) Drug delivery by supramolecular design. Chem Soc Rev
46(21):6600–6620
18. Cohen Y, Avram L, Frish L (2005) Diffusion
NMR spectroscopy in supramolecular and combinatorial chemistry: an old parameter—new
insights. Angew Chem Int Ed 44(4):520–554
Christos M. Chatzigiannis et al.